Mr. Denne to Accelerate Biote’s Expansion into Men’s Hormone Replacement Therapy Market IRVING, Texas --(BUSINESS WIRE)--Apr. 10, 2023-- Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced that John Denne

Achieved Full Year 2022 Record Revenue and Adjusted EBITDA for Full Year 2022 Expect 2023 Revenue of $190-200 million and Adjusted EBITDA of $56-60 million Significantly Increased Trading Liquidity with Recent Successful Secondary Offering IRVING, Texas --(BUSINESS WIRE)--Mar.

Study reports the patient also experienced “increased energy, recovery, and benefits to his sleep apnea” as well as being able to “remove supportive fracture hardware in one year” IRVING, Texas --(BUSINESS WIRE)--Mar. 27, 2023-- In a case study, a 54-year-old male patient with a spontaneous

IRVING, Texas --(BUSINESS WIRE)--Mar. 2, 2023-- biote   Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading innovator in preventive health care through the delivery of personalized hormone therapy, today announced its participation in the 35 th Annual Roth Conference , to be held March

IRVING, Texas --(BUSINESS WIRE)--Feb. 9, 2023-- Biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading provider of preventive health care through the delivery of personalized hormone therapy, today announced the Company will provide fourth quarter and full year financial results on

IRVING, Texas --(BUSINESS WIRE)--Jan. 9, 2023-- biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading provider of preventive health care through the delivery of personalized hormone therapy, today announced the closing of its previously announced underwritten public offering of 8,500,000

IRVING, Texas --(BUSINESS WIRE)--Jan. 5, 2023-- biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”), a leading provider of preventive health care through the delivery of personalized hormone therapy, today announced the pricing of an underwritten public offering of its Class A common stock by

IRVING, Texas --(BUSINESS WIRE)--Nov. 10, 2022-- biote   Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading innovator in preventive health care through the delivery of personalized hormone therapy, today announced its participation in the Jefferies London Healthcare Conference , November

Strong Third Quarter Revenue of $42 million Driven by Growth in Procedures 2022 Revenue and Adjusted EBITDA Expected at Upper End of Guidance IRVING, Texas --(BUSINESS WIRE)--Nov. 8, 2022-- Biote (NASDAQ: BTMD), a leading provider of preventive health care through the delivery of personalized

IRVING, Texas --(BUSINESS WIRE)--Nov. 7, 2022-- biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading innovator in preventive health care through the delivery of personalized hormone therapy, today announced the appointment of Debby Morris to Biote’s Board of Directors. Ms.